CONSENT JUDGMENT

MIRANDA M. DU, District Judge.

Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited (hereinafter collectively "Amarin"), and Teva Pharmaceuticals USA, Inc. (hereinafter "Teva"), the parties in the above-captioned actions, have agreed to terms and conditions representing a negotiated settlement of the actions and have set forth those terms and conditions in a Settlement Agreement (the "Settlement Agreement"). Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in the actions, as follows:

ORDERED, ADJUDGED AND DECREED as follows:

This District Court has jurisdiction over the subject matter of the above actions and has personal jurisdiction over the parties.

As used in this Consent Judgment, the terms "Teva Product," "Approved Vacepa Product," "Generic Icosapent Ethyl Product," "Licensed Patents," and "Affiliate" shall have the meanings assigned to them in the Settlement Agreement.

Teva admits that the Teva Product infringes the Licensed Patents and that the Licensed Patents and all the claims contained therein are each valid and enforceable in all respects. This admission is without prejudice to any claim, defense or counterclaim (including non-infringement, invalidity, unenforceability and unpatentability) in any future action regarding both (a) the Licensed Patents and (b) a product other than a Generic Icosapent Ethyl product and other than the Teva Product.

Unless otherwise specifically authorized pursuant to the Settlement Agreement, Teva, including any of its Affiliates, successors and assigns, is enjoined from infringing the Licensed Patents, on its own part or through any Affiliate, by making, having made, using, selling, offering to sell, importing or distributing of the Teva Product.

Unless otherwise specifically authorized pursuant to the Settlement Agreement, Teva is hereby enjoined and estopped during the term of each of the Licensed Patents from making any challenge to the validity or enforceability of the Licensed Patents and from asserting that the Teva Product does not infringe any of the Licensed Patents. Amarin acknowledges that Teva is entitled to maintain its Paragraph IV certification to the Licensed Patents with respect to the Teva Product pursuant to 21 C.F.R. § 314.94(a)(12)(v).

This Consent Judgment does not impact the U.S. Food and Drug Administration's ability to grant final approval of the Teva Product at any time.

Compliance with this Consent Judgment may be enforced by Amarin and its successors in interest, or assigns, as permitted by the terms of the Settlement Agreement.

This District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement.

All claims, counterclaims, affirmative defenses and demands in these actions are hereby dismissed with prejudice and without costs, disbursements or attorneys' fees to any party.

IT IS SO ORDERED.